Targeting LIpid MEtabolism in Cancer and Neurodegenerative Diseases

Arrow Down

At Lime, we are inventing breakthrough lipid-targeting therapeutics using our novel drug discovery platform.

Lime Therapeutics is a New York City-based Memorial Sloan Kettering Cancer Center spin-out utilizing a novel high-throughput screening approach for discovering lipid-targeting drugs for treating cancer and neurodegenerative diseases. Using our proprietary approach, we have identified and patented a lead drug candidate that increased mice lifespan in a metastatic non-small cell lung cancer model by 50%. This is the first drug in our planned pipeline of drugs targeting lipid metabolism. The time for lipid-altering therapeutics is now and we look forward to engaging with you to discuss how we are meeting this need.

 
 

Leadership

Scientific Advisory Board

vanderheiden.jpg
schwartz.jpg

Robert Schwartz, MD, PhD

Weill Cornell Medicine

Matthew
Vander Heiden, MD, PhD

Massachusetts Institute of Technology (MIT)

perera.jpg

Rushika Perera, PhD

University of California,
San Francisco

tammela.jpg
jiang.jpg

Xuejun Jiang, PhD

Tuomas Tammela, MD, PhD

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center

Business Advisors

klausner.jpg
rosenbaum.jpg

Avi Rosenbaum, PhD

Arthur Klausner, MBA

Life Sciences and Venture Capital Consultant

Advisors.bio

Parul Chachra Picture.jpeg

Parul Chachra, PhD, MBA

X (Google)

 
 
 
 

Technology

Creating Lipid-Altering Therapeutics

lipidsense-outlined.png

Cancers feed off nutrients, such as lipids (fats). In addition, excess lipid buildup is a hallmark of neurodegenerative disorders. Despite this, efforts to target lipid metabolism in cancer and neurodegenerative disorders have remained elusive due to lack of technology. 

 

We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a well-plate format, and in live animals. 

 

We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in neurodegenerative disorders.

The primary indication for our lead drug candidate is non-small cell lung cancer. We are also exploring therapeutic opportunities for this and other drugs in our pipeline for pancreatic, colorectal, and kidney cancer. Collectively, these four cancers represent a $50B total addressable market (TAM) and 462,000 patients diagnosed annually in the US.

Publications

A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.  

Prakrit V. Jena, Daniel Roxbury, et. al.  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/

An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.  

Thomas V. Galassi, Prakrit V. Jena, et. al.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543545/

 

Our Supporters

Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):

Allston-Venture-Fund-wText.png
American-Chemical-Society-(ACS)-BIOT.png
Biolabs_atNYUL_highres.png
BFF_2018logo_BLACK-copy_0.png
EFL-Logo.png
HBS.png

Kent Johnson

Former CFO, BioLegend

LGB_edited.png
Little Green Bamboo

Invest together. Grow together.

Startup-Legal-Garage.png
Pillar-VC.png
XSeed logo (2)_edited.png

If interested in pursuing an investment opportunity, please reach out.

 

Careers

We are working on job descriptions for a target validation scientist (PhD level), and a lab technician, but until then, please submit a resume below for further consideration and check back here for updates. Must be able to work in-office in New York City. 

 
 

Contact

Headquarters

BioLabs@NYULangone

180 Varick St., Floor 6

New York, NY 10014

Inquiries

For any inquiries, please fill out the following form.

Thank you for submitting your message!